Tests safety of plamotamab in adults with rheumatoid arthritis
Tests plamotamab's safety in adults with rheumatoid arthritis.
Key facts
- Who runs it
- Xencor, Inc.
- Where
- Auckland, New ZealandSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 68 people, planned
- Started
- 21 Oct 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- Plamotamab
- Record updated
- 3 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active rheumatoid arthritis. It tests the safety of plamotamab, given as an injection under the skin.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Moderately to severely active rheumatoid arthritis (RA), diagnosed at least 3 months before screening.
- Earlier treatment
- Inadequate response, loss of response or intolerance to available RA therapies. Stable doses of RA medicines before screening.
Main reasons for not taking part
- Major surgery within 12 weeks before screening or planned within 12 months after dosing
- Recurrent infections or an active, clinically significant infection
- Active or untreated latent tuberculosis
- Cancer or lymphoproliferative disease within the previous 5 years
- Uncontrolled heart, lung, kidney, liver, hormone or gut disease
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
- Inadequate response to, loss of response to, or intolerance to available RA therapies
- Stable doses of RA medications prior to screening
- Use of highly effective methods of contraception
Who cannot take part
- Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
- Recurrent infections or active clinically significant infection
- Active or untreated latent tuberculosis
- Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
- Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease; Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol
This trial is currently available in New Zealand.
Also in 2 other countries, 2 sites
- AucklandHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
The group in the trial
- Dose EscalationTreatment being tested
Plamotamab administered SC
Treatment: Plamotamab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
- Plain-language title
- Tests safety of plamotamab in adults with rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 August 2026